Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 372 entries
Sorted by: Best Match Show Resources per page
Ion suppression effect in desorption electrospray ionization and electrospray ionization mass spectrometry.

Rapid communications in mass spectrometry : RCM

Wang Z, Zhu H, Huang G.
PMID: 28857292
Rapid Commun Mass Spectrom. 2017 Dec 15;31(23):1957-1962. doi: 10.1002/rcm.7977.

RATIONALE: Although it is claimed that desorption electrospray ionization (DESI) causes less ion suppression effects than electrospray ionization (ESI), a related investigation with quantification measurement of ion suppression effects is absent. Herein, a comparative analysis of ion suppression effects...

Cite
Wang Z, Zhu H, Huang G. Ion suppression effect in desorption electrospray ionization and electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2017;31(23):1957-1962doi: 10.1002/rcm.7977.
Wang, Z., Zhu, H., & Huang, G. (2017). Ion suppression effect in desorption electrospray ionization and electrospray ionization mass spectrometry. Rapid communications in mass spectrometry : RCM, 31(23), 1957-1962. https://doi.org/10.1002/rcm.7977
Wang, Zheng, et al. "Ion suppression effect in desorption electrospray ionization and electrospray ionization mass spectrometry." Rapid communications in mass spectrometry : RCM vol. 31,23 (2017): 1957-1962. doi: https://doi.org/10.1002/rcm.7977
Wang Z, Zhu H, Huang G. Ion suppression effect in desorption electrospray ionization and electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2017 Dec 15;31(23):1957-1962. doi: 10.1002/rcm.7977. PMID: 28857292.
Copy Download .nbib Format: NLM
Sheathless interface to match flow rate of capillary electrophoresis with electrospray mass spectrometry using regular-sized capillary.

Rapid communications in mass spectrometry : RCM

Yin Y, Li G, Guan Y, Huang G.
PMID: 27539418
Rapid Commun Mass Spectrom. 2016 Aug;30:68-72. doi: 10.1002/rcm.7621.

RATIONALE: The flow rate match has been a great challenge when coupling capillary electrophoresis (CE) with electrospray ionization mass spectrometry (ESI-MS). Conventional CE-ESI-MS interfaces used liquid sheath flow, narrowed capillary or additional pressure to meet this requirement; sacrifice of...

Cite
Yin Y, Li G, Guan Y, et al. Sheathless interface to match flow rate of capillary electrophoresis with electrospray mass spectrometry using regular-sized capillary. Rapid Commun Mass Spectrom. 2016;30:68-72doi: 10.1002/rcm.7621.
Yin, Y., Li, G., Guan, Y., & Huang, G. (2016). Sheathless interface to match flow rate of capillary electrophoresis with electrospray mass spectrometry using regular-sized capillary. Rapid communications in mass spectrometry : RCM, 3068-72. https://doi.org/10.1002/rcm.7621
Yin, Yue, et al. "Sheathless interface to match flow rate of capillary electrophoresis with electrospray mass spectrometry using regular-sized capillary." Rapid communications in mass spectrometry : RCM vol. 30 (2016): 68-72. doi: https://doi.org/10.1002/rcm.7621
Yin Y, Li G, Guan Y, Huang G. Sheathless interface to match flow rate of capillary electrophoresis with electrospray mass spectrometry using regular-sized capillary. Rapid Commun Mass Spectrom. 2016 Aug;30:68-72. doi: 10.1002/rcm.7621. PMID: 27539418.
Copy Download .nbib Format: NLM
Deprotonation effect of tetrahydrofuran-2-carbonitrile buffer gas dopant in ion mobility spectrometry.

Rapid communications in mass spectrometry : RCM

Fernandez-Maestre R, Meza-Morelos D, Wu C.
PMID: 27173115
Rapid Commun Mass Spectrom. 2016 Jun 15;30(11):1332-8. doi: 10.1002/rcm.7567.

RATIONALE: When dopants are introduced into the buffer gas of an ion mobility spectrometer, spectra are simplified due to charge competition.METHODS: We used electrospray ionization to inject tetrahydrofuran-2-carbonitrile (F, 2-furonitrile or 2-furancarbonitrile) as a buffer gas dopant into an...

Cite
Fernandez-Maestre R, Meza-Morelos D, Wu C. Deprotonation effect of tetrahydrofuran-2-carbonitrile buffer gas dopant in ion mobility spectrometry. Rapid Commun Mass Spectrom. 2016;30(11):1332-8doi: 10.1002/rcm.7567.
Fernandez-Maestre, R., Meza-Morelos, D., & Wu, C. (2016). Deprotonation effect of tetrahydrofuran-2-carbonitrile buffer gas dopant in ion mobility spectrometry. Rapid communications in mass spectrometry : RCM, 30(11), 1332-8. https://doi.org/10.1002/rcm.7567
Fernandez-Maestre, Roberto, et al. "Deprotonation effect of tetrahydrofuran-2-carbonitrile buffer gas dopant in ion mobility spectrometry." Rapid communications in mass spectrometry : RCM vol. 30,11 (2016): 1332-8. doi: https://doi.org/10.1002/rcm.7567
Fernandez-Maestre R, Meza-Morelos D, Wu C. Deprotonation effect of tetrahydrofuran-2-carbonitrile buffer gas dopant in ion mobility spectrometry. Rapid Commun Mass Spectrom. 2016 Jun 15;30(11):1332-8. doi: 10.1002/rcm.7567. PMID: 27173115.
Copy Download .nbib Format: NLM
A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension.

British journal of clinical pharmacology

McNeil JJ, Louis WJ.
PMID: 26635160
Br J Clin Pharmacol. 1979 Apr;8:163S-6S. doi: 10.1111/j.1365-2125.1979.tb04774.x.

1 This study was designed to compare in a double-blind randomized crossover trial, atenolol, labetalol, metoprolol and pindolol. Considerable differences in dose (atenolol 138 +/- 13 mg daily; labetalol 308 +/- 34 mg daily; metoprolol 234 +/- 22 mg...

Cite
McNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979;8:163S-6Sdoi: 10.1111/j.1365-2125.1979.tb04774.x.
McNeil, J. J., & Louis, W. J. (1979). A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. British journal of clinical pharmacology, 8163S-6S. https://doi.org/10.1111/j.1365-2125.1979.tb04774.x
McNeil, J J, and Louis, W J. "A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension." British journal of clinical pharmacology vol. 8 (1979): 163S-6S. doi: https://doi.org/10.1111/j.1365-2125.1979.tb04774.x
McNeil JJ, Louis WJ. A double-blind crossover comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br J Clin Pharmacol. 1979 Apr;8:163S-6S. doi: 10.1111/j.1365-2125.1979.tb04774.x. PMID: 26635160.
Copy Download .nbib Format: NLM
Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine.

Redox report : communications in free radical research

Wasil M, Kelly FJ.
PMID: 27405835
Redox Rep. 1995 Nov;1(5):361-7. doi: 10.1080/13510002.1995.11747012.

The angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine, protect myocardial tissue from ischaemia/reperfusion-induced injury. Although both drugs have well established, independent mechanisms of cardiac protection, they may also have antioxidant activity which could contribute to their...

Cite
Wasil M, Kelly FJ. Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox Rep. 1995;1(5):361-7doi: 10.1080/13510002.1995.11747012.
Wasil, M., & Kelly, F. J. (1995). Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox report : communications in free radical research, 1(5), 361-7. https://doi.org/10.1080/13510002.1995.11747012
Wasil, M, and Kelly, F J. "Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine." Redox report : communications in free radical research vol. 1,5 (1995): 361-7. doi: https://doi.org/10.1080/13510002.1995.11747012
Wasil M, Kelly FJ. Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox Rep. 1995 Nov;1(5):361-7. doi: 10.1080/13510002.1995.11747012. PMID: 27405835.
Copy Download .nbib Format: NLM
Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin.

Indian journal of pharmaceutical sciences

Sarfraz RM, Khan HU, Mahmood A, Ahmad M, Maheen S, Sher M.
PMID: 25767322
Indian J Pharm Sci. 2015 Jan-Feb;77(1):83-90. doi: 10.4103/0250-474x.151602.

In this study, mouth-disintegrating tablets of atenolol and atorvastatin combination were formulated using superdisintegrants to impart fast disintegration. Fifteen formulations were prepared based on different concentrations of two superdisintegrants, croscarmellose sodium and Kyron-T134. Three different techniques such as direct...

Cite
Sarfraz RM, Khan HU, Mahmood A, et al. Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin. Indian J Pharm Sci. 2015;77(1):83-90doi: 10.4103/0250-474x.151602.
Sarfraz, R. M., Khan, H. U., Mahmood, A., Ahmad, M., Maheen, S., & Sher, M. (2015). Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin. Indian journal of pharmaceutical sciences, 77(1), 83-90. https://doi.org/10.4103/0250-474x.151602
Sarfraz, R M, et al. "Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin." Indian journal of pharmaceutical sciences vol. 77,1 (2015): 83-90. doi: https://doi.org/10.4103/0250-474x.151602
Sarfraz RM, Khan HU, Mahmood A, Ahmad M, Maheen S, Sher M. Formulation and evaluation of mouth disintegrating tablets of atenolol and atorvastatin. Indian J Pharm Sci. 2015 Jan-Feb;77(1):83-90. doi: 10.4103/0250-474x.151602. PMID: 25767322; PMCID: PMC4355887.
Copy Download .nbib Format: NLM
Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital.

Avicenna journal of medicine

Sivva D, Mateti UV, Neerati VM, Thiruthopu NS, Martha S.
PMID: 25878964
Avicenna J Med. 2015 Apr-Jun;5(2):29-35. doi: 10.4103/2231-0770.154194.

OBJECTIVE: The objective of the study was to assess the incidence and pattern of drug-drug interactions (DDIs) in hypertensive patients by using Micromedex and Medscape databases.MATERIALS AND METHODS: A prospective observational study was carried out in a superspeciality hospital...

Cite
Sivva D, Mateti UV, Neerati VM, et al. Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna J Med. 2015;5(2):29-35doi: 10.4103/2231-0770.154194.
Sivva, D., Mateti, U. V., Neerati, V. M., Thiruthopu, N. S., & Martha, S. (2015). Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna journal of medicine, 5(2), 29-35. https://doi.org/10.4103/2231-0770.154194
Sivva, Divya, et al. "Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital." Avicenna journal of medicine vol. 5,2 (2015): 29-35. doi: https://doi.org/10.4103/2231-0770.154194
Sivva D, Mateti UV, Neerati VM, Thiruthopu NS, Martha S. Assessment of drug-drug interactions in hypertensive patients at a superspeciality hospital. Avicenna J Med. 2015 Apr-Jun;5(2):29-35. doi: 10.4103/2231-0770.154194. PMID: 25878964; PMCID: PMC4394569.
Copy Download .nbib Format: NLM
Is it time to replace propranolol with carvedilol for portal hypertension?.

World journal of gastrointestinal endoscopy

Abid S, Ali S, Baig MA, Waheed AA.
PMID: 25992192
World J Gastrointest Endosc. 2015 May 16;7(5):532-9. doi: 10.4253/wjge.v7.i5.532.

Beta-adrenergic receptor antagonists (β-blockers) have been well established for use in portal hypertension for more than three decades. Different Non-selective β-blockers like propranolol, nadolol, timolol, atenolol, metoprolol and carvedilol have been in clinical practice in patients with cirrhosis. Carvedilol...

Cite
Abid S, Ali S, Baig MA, et al. Is it time to replace propranolol with carvedilol for portal hypertension?. World J Gastrointest Endosc. 2015;7(5):532-9doi: 10.4253/wjge.v7.i5.532.
Abid, S., Ali, S., Baig, M. A., & Waheed, A. A. (2015). Is it time to replace propranolol with carvedilol for portal hypertension?. World journal of gastrointestinal endoscopy, 7(5), 532-9. https://doi.org/10.4253/wjge.v7.i5.532
Abid, Shahab, et al. "Is it time to replace propranolol with carvedilol for portal hypertension?." World journal of gastrointestinal endoscopy vol. 7,5 (2015): 532-9. doi: https://doi.org/10.4253/wjge.v7.i5.532
Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace propranolol with carvedilol for portal hypertension?. World J Gastrointest Endosc. 2015 May 16;7(5):532-9. doi: 10.4253/wjge.v7.i5.532. PMID: 25992192; PMCID: PMC4436921.
Copy Download .nbib Format: NLM
Postmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in Egypt.

Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit

Badawi MA, Wagdy E, Nasr M, Etman MA, El-Khordagui LK, Khalil SA.
PMID: 24995741
East Mediterr Health J. 2014 Jan 09;19:S166-71.

Concerns have been raised regarding the postmarketing quality of generic drugs. This study assessed the pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol tablets in 24 healthy male volunteers in a single-dose, open, randomized, two-period crossover study under...

Cite
Badawi MA, Wagdy E, Nasr M, et al. Postmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in Egypt. East Mediterr Health J. 2014;19:S166-71
Badawi, M. A., Wagdy, E., Nasr, M., Etman, M. A., El-Khordagui, L. K., & Khalil, S. A. (2014). Postmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in Egypt. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit, 19S166-71.
Badawi, M A, et al. "Postmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in Egypt." Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit vol. 19 (2014): S166-71.
Badawi MA, Wagdy E, Nasr M, Etman MA, El-Khordagui LK, Khalil SA. Postmarketing pharmacokinetic and pharmacodynamic equivalence of generic and brand atenolol in Egypt. East Mediterr Health J. 2014 Jan 09;19:S166-71. PMID: 24995741.
Copy Download .nbib Format: NLM
Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies.

BMJ global health

Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S.
PMID: 28588970
BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016.

The Interagency Emergency Health Kit (IEHK) provides a standard package of medicines and simple medical devices for aid agencies to use in emergencies such as disasters and armed conflicts. Despite the increasing burden of non-communicable diseases (NCDs) in such...

Cite
Tonelli M, Wiebe N, Nadler B, et al. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016;1(3):e000128doi: 10.1136/bmjgh-2016-000128.
Tonelli, M., Wiebe, N., Nadler, B., Darzi, A., & Rasheed, S. (2016). Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ global health, 1(3), e000128. https://doi.org/10.1136/bmjgh-2016-000128
Tonelli, Marcello, et al. "Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies." BMJ global health vol. 1,3 (2016): e000128. doi: https://doi.org/10.1136/bmjgh-2016-000128
Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016. PMID: 28588970; PMCID: PMC5321368.
Copy Download .nbib Format: NLM
Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC).

Frontiers in pharmacology

Karam MC, Merckbawi R, Salman S, Mobasheri A.
PMID: 26913003
Front Pharmacol. 2016 Feb 15;7:22. doi: 10.3389/fphar.2016.00022. eCollection 2016.

Infection with a high dose of the intracellular parasitic protozoan Leishmania major induces a sustained hyperalgesia in susceptible BALB/c mice accompanied by up-regulation of the pro-inflammatory cytokines IL-1β and IL-6. Interleukin-13 (IL-13) has been shown to reduce this hyperalgesia...

Cite
Karam MC, Merckbawi R, Salman S, et al. Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Front Pharmacol. 2016;7:22doi: 10.3389/fphar.2016.00022.
Karam, M. C., Merckbawi, R., Salman, S., & Mobasheri, A. (2016). Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Frontiers in pharmacology, 722. https://doi.org/10.3389/fphar.2016.00022
Karam, Marc C, et al. "Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC)." Frontiers in pharmacology vol. 7 (2016): 22. doi: https://doi.org/10.3389/fphar.2016.00022
Karam MC, Merckbawi R, Salman S, Mobasheri A. Atenolol Reduces Leishmania major-Induced Hyperalgesia and TNF-α Without Affecting IL-1β or Keratinocyte Derived Chemokines (KC). Front Pharmacol. 2016 Feb 15;7:22. doi: 10.3389/fphar.2016.00022. eCollection 2016. PMID: 26913003; PMCID: PMC4753302.
Copy Download .nbib Format: NLM
β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature.

Open heart

DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH.
PMID: 25821584
Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015.

β-Blockers (BBs) are an essential class of cardiovascular medications for reducing morbidity and mortality in patients with heart failure (HF). However, a large body of data indicates that BBs should not be used as first-line therapy for hypertension (HTN)....

Cite
DiNicolantonio JJ, Fares H, Niazi AK, et al. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015;2(1):e000230doi: 10.1136/openhrt-2014-000230.
DiNicolantonio, J. J., Fares, H., Niazi, A. K., Chatterjee, S., D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., Lavie, C. J., Bell, D. S., & O'Keefe, J. H. (2015). β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open heart, 2(1), e000230. https://doi.org/10.1136/openhrt-2014-000230
DiNicolantonio, James J, et al. "β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature." Open heart vol. 2,1 (2015): e000230. doi: https://doi.org/10.1136/openhrt-2014-000230
DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015. PMID: 25821584; PMCID: PMC4371808.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 372 entries